Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 3/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | ARG1 | P05089 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.30 |
| ▸ | RAD52 | P43351 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL947556 | 0.98 | CXCR4 (0.39) | CXCR4HRH3CYP1A2HRH1 | |
| SCHEMBL947318 | 0.92 | CXCR4 (0.40) | CXCR4HRH3CYP1A2HRH1ARG1 | |
| SCHEMBL945963 | 0.83 | KEAP1 (0.38) | HRH3CYP1A2HRH1MAPK1SMN1; SMN2 | |
| SCHEMBL945748 | 0.82 | CHRM5 (0.36) | HRH3 | |
| SCHEMBL11555193 | 0.80 | CHRM5 (0.33) | — | |
| SCHEMBL945435 | 0.73 | ATM (0.44) | SMN1; SMN2 | |
| SCHEMBL1489944 | 0.73 | CYP1A2 (0.47) | HRH3CYP1A2HRH4RAD52 | |
| SCHEMBL5488980 | 0.71 | CHRM5 (0.32) | CXCR4HRH3 | |
| SCHEMBL5819709 | 0.71 | MAOB (0.37) | CXCR4 | |
| SCHEMBL161118 | 0.71 | CYP1A2 (0.44) | HRH3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989446-B2 | 4-amino 5-cyanopyrimidine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-08-02 | — | — | US | disclosed |
| US-20110009620-A1 | 4-Amino-5-cyanopyrimidine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. | 2011-01-13 | — | — | US | disclosed |
| US-7834002-B2 | 4-amino-5-cyanopyrimidine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| US-20080182854-A1 | 4-Amino-5-Cyanopyrimidine Derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-07-31 | — | — | US | disclosed |
| EP-1740574-B1 | 4-AMINO-5-CYANOPYRIMIDINE DERIVATIVES | OTSUKA PHARMA CO LTD (JP) | 2007-06-27 | — | — | EP | disclosed |
| EP-1740574-A2 | 4-AMINO-5-CYANOPYRIMIDINE DERIVATIVES | Otsuka Pharmaceutical Company, Limited (JP) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005105778-A2 | 4-AMINO-5-CYANOPYRIMIDINE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009620-A1 | 4-Amino-5-cyanopyrimidine derivatives | ADORA2A, ADORA1, ADORA3 | CXCR4 871/4885HRH3 1003/4885CYP1A2 497/4885 |
| US-20080182854-A1 | 4-Amino-5-Cyanopyrimidine Derivatives | ADORA2A, ADORA1, ADORA3 | CXCR4 871/4885HRH3 1003/4885CYP1A2 497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.